OrganOx, an organ medical technology company, raised $142 million in equity financing to accelerate growth opportunities in the global market.
The funding round was led by new investor HealthQuest Capital with backing from existing investors BGF, Lauxera Capital Partners, University of Oxford, Technikos, the Oxford Technology and Innovations Fund, and Longwall Ventures, along with additional new investors Sofina, Soleus Capital, and Avidity Partners.
“OrganOx’s financial profile is unparalleled, and partnering with leading investors in this transaction – new and existing – further strengthens us to support the success of our current customers, to expand our customer base, and to enter new markets,” said Steve Deitsch, Chief Financial Officer at OrganOx.
OrganOx is a commercial-stage organ technology company, spun out of the University of Oxford in 2008, developing technologies to improve outcomes for patients with acute or chronic organ failure. The OrganOx metra® is a normothermic machine perfusion (NMP) platform approved in the U.S., Europe, Canada, and Australia.
The platform has been utilized in over 5,000 liver transplants to date to keep donor livers in a metabolically active state outside the body so that functional assessment of the organ can be performed prior to transplant, leading to an increased number of organs available for transplant.